https://nova.newcastle.edu.au/vital/access/ /manager/Index en-au 5 https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:51659 Wed 13 Sep 2023 10:02:28 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:31507 Phyllanthus amarus (P. amarus) has been used as a medicinal plant for the prevention and treatment of chronic ailments such as diabetes, hepatitis, and cancer. Methods: The physicochemical properties, antioxidant and cytotoxic activities of crude extracts and fractions from P. amarus were determined using spectrophotometric method. Results: The P. amarus methanol (PAM) extract had lower levels of residual moisture (7.40%) and water activity (0.24) and higher contents of saponins, phenolics, flavonoids, and proanthocyanidins (1657.86 mg escin equivalents, 250.45 mg gallic acid equivalents, 274.73 mg rutin equivalents and 61.22 mg catechin equivalents per g dried extract, respectively) than those of the P. amarus water (PAW) extract. The antioxidant activity of PAM extract was significantly higher (p < 0.05) than that of the PAW extract, PAM fractions, and phyllanthin (known as a major compound in the P. amarus). Higher cytotoxic activity of PAM extract based on MTT assay on different cell lines including MiaPaCa-2 (pancreas), HT29 (colon), A2780 (ovarian), H460 (lung), A431 (skin), Du145 (prostate), BE2-C (neuroblastoma), MCF-7 (breast), MCF-10A (normal breast), and U87, SJ-G2, SMA (glioblastoma) was observed in comparison to the PAW extract and PAM fractions. The cytotoxic potential of the PAW extract (200 µg/mL), based on the CCK-8 assay on a pancreatic cancer cell line (MiaCaPa2) was significantly lower (p < 0.05) than those of gemcitabine (50 nM) and a saponin-enriched extract from quillajia bark at 200 µg/mL (a commercial product), but was significantly higher than that of phyllanthin at 2 µg/mL. Conclusions: The results achieved from this study reveal that the PA extracts are a potential source for the development of natural antioxidant products and/or novel anticancer drugs.]]> Tue 17 Mar 2020 11:32:49 AEDT ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:33410 65 years of age who received RT survived significantly longer than those who did not receive RT (aHR = 0.53, 95% CI = 0.52–0.54). However, as women aged, those with comorbidities were less likely to receive RT (adjusted p-trend by age < 0.0001). Conclusions: The development of decision-making tools to assist clinicians, and older women with breast cancer and comorbidities, are needed to facilitate personalized treatment plans regarding RT. This is particularly relevant as the population ages and the number of women with breast cancer is expected to increase in the near future.]]> Tue 03 Sep 2019 18:19:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34442 Tue 03 Sep 2019 18:00:55 AEST ]]> https://nova.newcastle.edu.au/vital/access/ /manager/Repository/uon:34443 Tue 03 Sep 2019 18:00:49 AEST ]]>